Amneal Pharmaceuticals, Inc. (AMRX)
Chart Events
Performance Outlook
| Previous Close | 3.9800 |
| Open | 4.0200 |
| Bid | 4.0500 x 1300 |
| Ask | 4.0700 x 3000 |
| Day's Range | 3.9700 - 4.0700 |
| 52 Week Range | 2.4000 - 5.7900 |
| Volume | 722,478 |
| Avg. Volume | 1,169,815 |
| Market Cap | 600.846M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | 9.74 |
| EPS (TTM) | 0.4180 |
| Earnings Date | Nov 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.44 |
- Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Satsuma Pharmaceuticals (NASDAQ: STSA) - P/E: 2.34 2. Acorda Therapeutics (NASDAQ: ACOR) - P/E: 0.69 3. Biogen (NASDAQ: BIIB) - P/E: 8.05 4. Amneal Pharmaceuticals (NYSE: AMRX) - P/E: 9.13 5. Bio-Rad Laboratories (NYSE: BIO) - P/E: 4.88This quarter, Satsuma Pharmaceuticals experienced a decrease in earnings per share, which was -0.65 in Q2 and is now -0.69. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Acorda Therapeutics reported earnings per share at -0.23, whereas in Q2 earnings per share sat at -0.35. Acorda Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Biogen's earnings per share for Q3 sits at 8.84, whereas in Q2, they were at 10.26. Biogen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Amneal Pharmaceuticals reported earnings per share at 0.16, whereas in Q2 earnings per share sat at 0.13. Amneal Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Bio-Rad Laboratories experienced an increase in earnings per share, which was 1.61 in Q2 and is now 3.0. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * A Preview Of Dick's Sporting Goods's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Zacks
Is Amneal Pharmaceuticals (AMRX) a Good Stock to Pick Now?
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
- Business Wire
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax® for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The product is available by prescription only and is associated with mild side effects such as nausea.
